Sirion Therapeutics Presentation at ARVO 2009
April 30, 2009
Sirion Therapeutics, Inc. announced that eight presentations related to the Company’s products, pipeline and research will be presented at ARVO.
These presentations include data related to Durezol(TM) (difluprednate ophthalmic emulsion) 0.05%, fenretinide, and retinal research programs from the Sirion San Diego, CA based drug discovery laboratory.
Durezol (difluprednate ophthalmic emulsion) 0.05% was approved by the U.S. Food & Drug Administration (FDA) after an expedited review in June 2008 for the treatment of post-operative inflammation and pain associated with ocular surgery. A supplemental New Drug Application (sNDA) was filed in December 2008 seeking an approval for Durezol as a treatment for endogenous anterior uveitis based partially on a head to head comparison to Pred Forte(R). The application was accepted in February 2009 by the agency and is under review.
Fenretinide is currently being evaluated in an ongoing phase II clinical trial in the treatment of geographic atrophy (GA) associated with age-related macular degeneration (AMD). The trial is a two year multicenter, randomized, double-masked, placebo controlled, dose-comparison in over 225 patients at 30 sites in the United States. A summary of the preliminary results of a planned interim analysis of this study was provided in a press release made by Sirion on April 15th, 2009. The ARVO presentations on fenretinide contain a more detailed analysis of the data obtained from the interim analysis.
Read the full release.
Jump down to form below to submit your own comments